Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Precisionlife Ltd.
Headquarters: Oxford, United Kingdom
Website: https://precisionlife.com/
Year Founded: 2013
Status: Private
BioCentury | Sep 19, 2024
Management Tracks
EMA names Sepodes CHMP chair, Bell leaving Valo as CEO, and more
Plus: Autolus hires Matthias Will as CDO, and updates from HotSpot, Prilenia, Frazier, BIA and BioCentriq
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Jun 4, 2024
Deals
Deals Report: Two pharmas license neuro assets, and M&A momentum continues
Plus: Galapagos-Adaptimmune enter TCR T cell deal, and digital therapeutics pioneer Akili opts for merger
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Oct 31, 2023
Product Development
Digital endpoints could be the key to patient-focused drug development
Digital endpoints offer unambiguous promise, but who will take on the risks and challenges of developing them?
BioCentury | Jul 22, 2023
Discovery & Translation
SIGLEC9 inhibition for glioblastoma; plus Long COVID genetic risks and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 2, 2023
Emerging Company Profile
PrecisionLife: learning from genetic interactions by cutting noise
U.K. company untangling genomic interactions to find targets in complex diseases
BioCentury | Feb 5, 2022
Deals
Feb. 4 Quick Takes: Vanda’s tradipitant records second Phase III miss
Plus: What, me worry? Arcellx goes public amid downdraft; and updates from Regio, J&J, Sanofi, PrecisionLife
Items per page:
1 - 8 of 8